VRTX Net income
Net income at Vertex Pharmaceuticals rose to $4.0B in fiscal 2025, the highest in the 5 years reported, from −$536M in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 875320 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$4.0B
FY2024 −$536M
HIGH$4.0B FY2025
LOW−$536M FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | $4.0B | +$4.5B |
| FY2024 | −$536M | $-4.2B |
| FY2023 | $3.6B | +$298M |
| FY2022 | $3.3B | +$980M |
| FY2021 | $2.3B | — |
More SAME DATA, OTHER VIEWS
Net income across coverage → · VRTX company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.